Alia Rahman is founder of Amplexd Therapeutics, an early-stage biotech company that has developed two novel, non-invasive treatments for HPV-induced cervical dysplasia, the precursor to cervical cancer. In 2007, Alia was herself diagnosed with the late-stage, high-grade cervical dysplasia. After undergoing a traumatic surgery, Alia continued to live with low-grade dysplasia. A decade later, another flare up to high-grade motivated her to develop an effective topical treatment in order to avoid further surgeries. In her kitchen, she combined two APIs and treated her own lesions, resulting in the first normal screening in over a decade. This finding formed the basis of Amplexd. Within six months, Amplexd had developed and patented two treatments: an intravaginal suppository and photodynamic therapy system as alternatives to “watch and wait” and invasive surgery, addressing all stages of dysplasia. Alia’s hopes are two-fold: to make non-invasive, low-cost treatments readily accessible to women all over the globe where screening and treatment options are scarce; and secondly, to see non-invasive therapies become the norm in HPV-care and gynecology more broadly. Alia holds a BASc in Engineering from the University of Waterloo and currently resides in Montreal, Canada. Alia is a multi-time medtech founder.

Dr. Ricky CHIU, Founder, Chairman, and CEO of PHASE Scientific International Limited, is an esteemed innovator and the lead inventor of PHASiFY™. With over 55 patents granted, PHASiFY™ has revolutionized low-concentration target molecule detection in diagnostics, advancing liquid biopsy and rapid point-of-care testing for early cancer and infectious disease detection. Ricky's efforts in leveraging his technologies for COVID diagnostics, including the first COVID rapid antigen test in Greater China to obtain FDA emergency use authorization, have earned him numerous prestigious recognitions. He has been honored with awards such as Ten Outstanding Young Persons of the World, Ten Outstanding Young Persons in Hong Kong, Young Industrialist of Hong Kong, and HKSAR Chief Executive's Commendation for Community Service. Through PHASiFY™, Ricky has made significant advancements in urine genetic testing. This technology can process and concentrate large urine volumes, extracting over 10 times more target analytes than the industry standard. It has led to the development of the world's first self-collection HPV urine test for cervical cancer, surpassing pap smear limitations. This innovative diagnostic process empowers women to conveniently manage their cervical health by detecting HPV in a non-intrusive and painless way.

Sarah Robinson is the Deputy Consul General to the British Consulate-General Hong Kong and Macao. This is her third tour to Hong Kong having previously served as Consul, Economics and Trade Policy, in 2019, and Second Secretary Political in 2004. Sarah joined the Foreign and Commonwealth Office in 2000. She has previously served as Deputy Head of Consular Assistance and headed up the Overseas Passport Management Unit, the Detainee Inquiry Unit, and the Prevent Counter Terrorism Team. She also served as a Desk Officer on Cyprus and on EU Public Diplomacy. Outside the FCDO Sarah worked for the Department for Education and Employment and also spent time seconded to the EU Commission and as a Parliamentary Assistant in the European Parliament. She has a degree in European Politics and Legislative Studies and is currently studying for a masters in Executive Coaching. Sarah speaks Cantonese and reads Chinese.